Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.1K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.4K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.4K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

499
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
499
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.0K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.0K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.4K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.4K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.0K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic impact of pleural effusion in acute heart failure and its link to diuretic therapy.

The American journal of medicine·2026
Same author

Incidence, risk factors and management of paradoxical reaction in central nervous system tuberculosis in the United Kingdom.

The Journal of infection·2026
Same author

Biomarker-defined congestion profiles in very old adults with acute heart failure: beyond ejection fraction classification.

European geriatric medicine·2026
Same author

Safety evaluation of the food enzyme glucan 1,4-α-maltohydrolase from the genetically modified <i>Bacillus licheniformis</i> strain DP-Dzb115.

EFSA journal. European Food Safety Authority·2026
Same author

Bridging clinical and environmental reservoirs: antimicrobial resistance in the emerging pathogen <i>Shewanella algae</i>.

Antimicrobial agents and chemotherapy·2026
Same author

Safety evaluation of the food enzyme glucan 1,4-α-glucosidase from the genetically modified <i>Trichoderma reesei</i> strain DP-Nzh109.

EFSA journal. European Food Safety Authority·2026

Related Experiment Video

Updated: Dec 26, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K

[Update on interstitial lung diseases].

Mauricio Salinas1, Matías Florenzano2, Verónica Wolff1

  • 1Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Revista Medica De Chile
|March 19, 2020
PubMed
Summary

Interstitial lung diseases (ILDs) are chronic and challenging. Recent advances improve understanding and treatment of ILDs, including idiopathic pulmonary fibrosis and hypersensitivity pneumonitis, with ongoing trials offering future hope.

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

678
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

754

Related Experiment Videos

Last Updated: Dec 26, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

678
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

754

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Genetics and Epidemiology of Chronic Diseases

Background:

  • Interstitial lung diseases (ILDs) represent a complex and diverse group of chronic respiratory conditions with often poor prognoses.
  • Significant progress has been made over the past two decades in understanding the epidemiology, pathology, genetics, and treatment of various ILDs.

Purpose of the Study:

  • To provide an updated summary of current knowledge on ILD classification, genetics, and therapeutic strategies.
  • To review recent advances in the diagnosis and management of specific ILDs, including idiopathic pulmonary fibrosis and hypersensitivity pneumonitis.
  • To discuss interstitial diseases associated with connective tissue diseases.

Main Methods:

  • Literature review and synthesis of recent research findings.
  • Summarization of updated information on ILD classification and genetic bases.
  • Review of current diagnostic and therapeutic approaches for selected ILDs.

Main Results:

  • The article presents updated information on the classification of ILDs.
  • New insights into the genetics and treatments for idiopathic pulmonary fibrosis are discussed.
  • Advances in diagnosing and managing hypersensitivity pneumonitis and ILDs linked to connective tissue diseases are reviewed.

Conclusions:

  • Continued research and clinical trials are crucial for advancing the treatment of interstitial lung diseases.
  • Improved understanding of genetic factors and disease mechanisms will facilitate personalized therapeutic strategies.
  • Ongoing clinical trials are expected to yield further insights and tools for better patient management.